Powerful Efficacy. Ensured Safety. Convenient Dosing. Renal safety Renal benefits with Empagliflozin and Linagliptin1,2 Zoom Zoom Renal benefits with EMPA and LINA1,2 Glyxambi® is not indicated in the treatment of CKD.* Exploratory endpoint in the EMPA-REG OUTCOME® trial.# Prespecified microvascular endpoint in the CARMELINA® trial.† Exploratory outcome in the CARMELINA® trial.FDC: Fixed-dose combination. EMPA: Empagliflozin. LINA: Linagliptin. HR: Hazard ratio.RRR: Relative risk reduction. UACR: Urine albumin-to-creatinine ratio. Cl: Confidence interval.CKD: Chronic kidney disease. References:Wanner C, et al. N Engl J Med. 2016;375:323-334.Rosenstock J, et al. JAMA. 2019;321(1):6 9-79. Why Glyxambi®? Why Glyxambi®? Guidelines Efficacy Pleiotropic benefits Cardiovascular safety Renal safety Other safety Differentiation v/s other FDCs Efficacy vs. Glimepiride Other benefits vs. Glimepiride